A tale of two cities – a look at two small immunotherapy biotechs

Going beyond anti-PD1 checkpoint blockade is important if we want to help more people respond to cancer immunotherapy

January 14, 2019

The challenges of bispecifics

FDA slaps a partial clinical hold for unwanted side effects, now what?

December 11, 2018

What can we learn from early IO trials?

There are a number of important lessons we can learn from early phase 1 trials. Here are some of them.

November 16, 2018

Pinning down potential new opportunities for IL–8 and 4–1BB

What is old is new again - a look at some forgotten oncology targets that are coming back in fashion

November 13, 2018

An analysis of Nektar’s latest PIVOT data and pipeline update

Update on PIVOT-02 with nivolumab plus NKTR-214 in 1L metastatic melanoma

November 12, 2018

How the microbiota impact response to cancer immunotherapy

The evolving story of how commensal microbiota can affect response to cancer immunotherapy

November 9, 2018

New developments in immune escape

Latest news and insights on immune escape mechanisms associated with cancer immunotherapy

November 8, 2018

SITC18 Preview and IO curiosities

An extensive round-up of what to expect from SITC18 ahead of the abstract reveal

November 2, 2018